Amendments to the Claims:

Please cancel claims 10-29 without prejudice. Please add new claims 30 - 38 as shown below in the list of Claims.

List of Claims:

Claims 1-29 (canceled).

Claim 30 (new). A method for determining clinical malignancy of FALS, characterized by isolating mutant SOD1 from a specimen taken from a FALS patient and evaluating the binding ability between said mutant SOD1 and TRAPδ.

Claim 31 (new). A method for determining clinical malignancy of FALS, characterized by isolating mutant SOD1 from a specimen taken from a FALS patient and evaluating the binding ability between said mutant SOD1, and NEDL1 and Dvl1.

Claim 32 (new). A method for determining clinical malignancy of FALS, characterized by isolating mutant SOD1 from a specimen taken from a FALS patient and evaluating the binding ability between said mutant SOD1 and NEDL1.

Claim 33 (new). The use of NEDL1 or its substrate for determination of clinical malignancy of FALS.

Claim 34 (new). The use of NEDL1 according to claim 4, characterized by using isolated mutant SOD1.

Claim 35 (new). The use of NEDL1 according to claim 5, characterized in that said substrate is TRAPδ or Dvl1.

Claim 36 (new). An inhibitor of interaction between mutant SOD1 and NEDL1 and/or its substrate.

Claim 37 (new). An inhibitor according to claim 36, characterized in that said substrate is TRAPδ or Dvl1.

Claim 38 (new). A method of screening for agents that are useful for treatment of FALS, characterized by determining whether or not a candidate drug is an inhibitor against interaction between mutant SOD1 and NEDL1 and/or its substrate in neurons.